Brokerages Anticipate OptiNose Inc (OPTN) to Announce -$0.71 EPS

Equities analysts predict that OptiNose Inc (NASDAQ:OPTN) will report earnings per share of ($0.71) for the current quarter, according to Zacks. Two analysts have made estimates for OptiNose’s earnings. The highest EPS estimate is ($0.68) and the lowest is ($0.73). OptiNose posted earnings of ($0.81) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 12.3%. The business is expected to issue its next earnings results on Monday, May 13th.

According to Zacks, analysts expect that OptiNose will report full-year earnings of ($2.86) per share for the current financial year, with EPS estimates ranging from ($3.01) to ($2.76). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.90) per share, with EPS estimates ranging from ($2.02) to ($1.77). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover OptiNose.

OptiNose (NASDAQ:OPTN) last released its earnings results on Wednesday, March 6th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.20. OptiNose had a negative net margin of 1,509.87% and a negative return on equity of 77.32%. The firm had revenue of $3.02 million for the quarter, compared to the consensus estimate of $2.60 million.

Several research firms have recently commented on OPTN. Royal Bank of Canada lowered their target price on shares of OptiNose to $25.00 and set an “outperform” rating on the stock in a report on Thursday, March 7th. Zacks Investment Research downgraded shares of OptiNose from a “hold” rating to a “sell” rating in a report on Wednesday, February 6th. ValuEngine downgraded shares of OptiNose from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $27.00 target price on shares of OptiNose in a report on Monday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $28.00.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in OptiNose in the fourth quarter worth $45,000. Stifel Financial Corp bought a new stake in OptiNose in the fourth quarter worth $63,000. Two Sigma Advisers LP bought a new stake in OptiNose in the fourth quarter worth $135,000. Rhumbline Advisers increased its position in OptiNose by 58.5% in the fourth quarter. Rhumbline Advisers now owns 23,709 shares of the company’s stock worth $147,000 after purchasing an additional 8,748 shares during the last quarter. Finally, MetLife Investment Advisors LLC bought a new stake in OptiNose in the third quarter worth $157,000. Institutional investors own 56.90% of the company’s stock.

Shares of OPTN stock traded down $0.31 during mid-day trading on Friday, hitting $9.89. The company had a trading volume of 164,168 shares, compared to its average volume of 150,713. OptiNose has a 52-week low of $5.66 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 8.01 and a current ratio of 8.28. The company has a market capitalization of $408.10 million, a PE ratio of -3.69 and a beta of 0.81.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Recommended Story: Return on Investment (ROI) Defined, Explained

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with's FREE daily email newsletter.